SCHEMBL27985185

SCHEMBL27985185

NC(=O)c1cccn2cccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 3/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
METAP2 P50579 1/20 0.42
ADRA1D P25100 1/20 0.41
BCAT2 O15382 1/20 0.41
PARP1 P09874 1/20 0.39
NPC1 O15118 2/20 0.39
GAA P10253 1/20 0.37
CTNNB1 P35222 1/20 0.37
SIRT1 Q96EB6 1/20 0.37
JAK2 O60674 3/20 0.37
JAK1 P23458 3/20 0.37
TYK2 P29597 3/20 0.37
JAK3 P52333 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28110444 0.98 KDM4E (0.43) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL2631222 0.88 MAPT (0.42) KDM4EALDH1A1MAPTHPGDTSHR
Hydrochloric Acid SCHEMBL16468136 0.86 KDM4E (0.41) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL25514677 0.80 ALDH1A1 (0.50) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL27972517 0.76 BCAT2 (0.49) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL27985191 0.74 LMNA (0.50) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL3261493 0.72 PLA2G2A (0.34) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL3458337 0.72 JAK2 (0.46) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL20305412 0.71 CLK1 (0.43) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL1420264 0.71 MKNK1 (0.47) KDM4EALDH1A1MAPTHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104066330-A Isoxazoline derivatives for controlling ectoparasites LILLY CO ELI 2014-09-24 CN claimed
US-20250368646-A1 TRICYCLIC FUSED WRN INHIBITORS NIMBUS WADJET INC (US) 2025-12-04 US disclosed
CN-110381738-A Pesticide and Parasiticidal vinyl isoxazoline compound 勃林格殷格翰动物保健美国公司 2019-10-25 CN disclosed
CN-105906655-A Isoxazoline derivatives used in the control of ectoparasites 安纳考尔医药公司 2016-08-31 CN disclosed
CN-104066330-B Isoxazoline derivatives for controlling ectoparasites ANACOR PHARMACEUTICALS, INC. (US) 2016-05-18 CN disclosed
CN-104066330-A Isoxazoline derivatives for controlling ectoparasites LILLY CO ELI 2014-09-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368646-A1 TRICYCLIC FUSED WRN INHIBITORS WRN, BLM, RECQL KDM4E 3402/4885ALDH1A1 3214/4885MAPT 3625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.